Journal of Medicinal Chemistry p. 5623 - 5642 (2018)
Update date:2022-08-15
Topics:
Wang, Feng
Jeon, Kyu Ok
Salovich, James M.
Macdonald, Jonathan D.
Alvarado, Joseph
Gogliotti, Rocco D.
Phan, Jason
Olejniczak, Edward T.
Sun, Qi
Wang, Shidong
Camper, Demarco
Yuh, Joannes P.
Shaw, J. Grace
Sai, Jiqing
Rossanese, Olivia W.
Tansey, William P.
Stauffer, Shaun R.
Fesik, Stephen W.
WDR5 is a chromatin-regulatory scaffold protein overexpressed in various cancers and a potential epigenetic drug target for the treatment of mixed-lineage leukemia. Here, we describe the discovery of potent and selective WDR5-WIN-site inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified several chemically distinct hit series that bind to the WIN site within WDR5. Members of a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole fragment class were expanded using a structure-based design approach to arrive at lead compounds with dissociation constants <10 nM and micromolar cellular activity against an AML-leukemia cell line. These compounds represent starting points for the discovery of clinically useful WDR5 inhibitors for the treatment of cancer.
View Morewebsite:http://www.josunpharma.com
Contact:+86-311-80715268 80766839
Address:No.39, Zhaiying Street, Shijaizhuang,Hebei,China
Tianjin Dongchang Fine Chemical Industry Co., Ltd.
Contact:+86-22-29894595
Address:Economic Developing Zone, Ji County, Tianjin, China
website:http://www.arromax.com
Contact:+86-0512-62959601 skype:aimmezhang
Address:Suite 401, Bldg A3, 218 Xinghu St.Suzhou Industrial Park 215123, P.R. China
Nanjing Habo Medical Technology Co., Ltd.
Contact:025-85769882
Address:No.108. Ganjiabian east. Qixia District .Nanjing
Anhui New Star Pharmaceutical Development Co., Ltd
Contact:013956922763
Address:Floor 3, F9A, F Workshop, No.110 Kexue Road, High-Tech Development Zone, Hefei, Anhui ,China
Doi:10.1007/BF00763697
(1986)Doi:10.1080/00397919608003762
(1996)Doi:10.1016/j.tet.2012.09.087
(2012)Doi:10.1021/acscatal.8b00923
(2018)Doi:10.1248/cpb.34.1950
(1986)Doi:10.1016/j.tet.2008.08.010
(2008)